11:14 AM
 | 
Nov 16, 2018
 |  BC Week In Review  |  Financial News  |  Completed Offerings

V-Bio, Gimv lead €37M Camel-IDS series A

Camelid-derived antibody company Camel-IDS N.V. (Brussels, Belgium) raised €37 million ($41.7 million) in a series A round Nov. 15 to support Phase II trials of lead brain metastatic breast cancer candidate, CAM-H2. V-Bio Ventures and Gimv led the round, which included co-lead investors HealthCap Advisor AB, Novo Seeds, Pontifax and BioMedPartners.

Camel-IDS CEO Ruth Devenyns...

Read the full 252 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >